SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: SH-1028 tabletsDrug: Placebo SH-1028 tablets
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 242
- Registration Number
- NCT06080776
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Tumor
- Interventions
- Drug: SH3765 tablet
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05015309
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: SH3809 tablet
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT04843033
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: [14C] SH-1028
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04810533
- Locations
- 🇨🇳
Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine, Nanjing, Jiangsu, China
The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028
Phase 1
- Conditions
- Healthy Male Volunteers
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04808648
- Locations
- 🇨🇳
the First Affiliated Hospital with Bengbu Medical College, Bengbu, Anhui, China
A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia
Phase 1
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Drug: SH1573 Capsules
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT04806659
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
Phase 2
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Drug: SHC014748M treatment
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT04470141
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT04431089
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: SH3051 capsule treatment
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT04423380
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT04239833
© Copyright 2025. All Rights Reserved by MedPath